SCIEX Reviews

VeraChem LLC was established in 2000 to advance computer-aided drug discovery. These methods are implemented in high-performance software and provide comprehensive support to users. This is a key strategy of VeraChem LLC for product development. Current VeraChem software capabilities include host-guest and protein-ligand binding affinity prediction, fast calculation and computation of partial atomic charges for druglike compounds, computation and force of energies and forces using all the most commonly used empirical force field, automatic generation and generation of alternate resonance forms for drug-like substances, conformational search using the powerful Tork algorithm and automatic detection and removal of topological and 3D-molecular symmetries. VeraChem's software packages were built from a modular code base.

We are a biotechnology company in clinical stage. We decode biology by integrating technological innovations across biology and chemistry to industrialize drug discovery. CRISPR genome editing and synthetic Biology allow for greater control over biology. Advanced robotics allows for reliable automation of complex laboratory research on an unprecedented scale. Neural network architectures allow for iterative analysis and inference from large, complex, in-house data sets. Cloud solutions increase the flexibility of high-performance computation. To build a next-generation biopharmaceutical business, we are using new technology to create virtuous learning cycles around datasets. A synchronized combination hardware, software, and data that is used to industrialize drug discovery. Redefining the traditional drug discovery process. One of the most extensive, broadest, and deepest pipelines in any technology-enabled drug company.